Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Progestins have tumor-stage specific effects that determine promotion, suppression: Study

Progestins are used in hormone replacement therapies to counteract the negative effects of estrogen on the uterus and reduce the risk of uterine cancer. However, evidence in recent studies and clinical trials has demonstrated that progestins increase the risk of breast cancer. Now, University of Missouri researchers have compared four types of progestins used in hormone replacement therapies and found significantly different outcomes on the progression of breast cancer in an animal model depending on the type of progestins used.

11 Aug 2010

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation, Inc. today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people's vitamin D daily intake amount in order to maximize the vitamin's contribution to reducing the frequency of many diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness.

10 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

GTx second-quarter net loss increases to $12.9 million

GTx, Inc. today reported financial results for the second quarter of 2010. The net loss for the quarter ended June 30, 2010 was $12.9 million compared with a net loss of $11.3 million for the quarter ended June 30, 2009. The net loss for the second quarter of 2010 included a $1.7 million non-cash impairment charge related to the conclusion of the Phase III clinical trial of toremifene 20 mg.

9 Aug 2010

Repros Therapeutics receives positive feedback from FDA for Androxal

Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.

9 Aug 2010

Shlomo Melmed appointed to Independent Citizen's Oversight Committee

Shlomo Melmed, M.D., senior vice president for academic affairs and dean of the medical faculty at Cedars-Sinai Medical Center, has been appointed by Gov. Arnold Schwarzenegger to the Independent Citizen's Oversight Committee, the governing board of the California Institute for Regenerative Medicine.

7 Aug 2010

Surgery offers high survival rate for prostate cancer patients: Study

Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies, according to a new study led by researchers at UCSF.The differences among therapies were more prominent at higher levels of cancer risk, and suggest, the researchers say, that in many cases surgery should play a greater role in treatment strategies for patients with prostate cancer that is likely to recur or spread.

7 Aug 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010.

7 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

Patheon, Dendreon announce signing of technology transfer agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.

6 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

New volume on Growth hormone therapy

Growth hormone (GH) has been used therapeutically for over 50 years. Since the development of a nearly unlimited supply of recombinant human GH in the mid-1980s, children with less severe GH deficiency can also profit from GH replacement therapy.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Excess maternal weight gain predicts high birth weight: Research

Expectant mothers who gain large amounts of weight tend to give birth to heavier infants who are at higher risk for obesity later in life. But it's never been proven that this tendency results from the weight gain itself, rather than genetic or other factors that mother and baby share. A large population-based study from Children's Hospital Boston, looking at two or more pregnancies in the same mother, now provides evidence that excess maternal weight gain is a strong, independent predictor of high birth weight.

5 Aug 2010

Scientists suggest home genetic tests may cause unnecessary stress

In the age of the Internet, where cybercondriacs are just a mouse click away from a diagnosis, do-it-yourself home genetics test may seem like the next logical step in managing health. But these tests, which are relatively new and available online, are often not comprehensive and may cause unnecessary stress, warns Suzanne Mahon, DNSc., a clinical professor of hematology and oncology at Saint Louis University.

5 Aug 2010

Pregnancy weight gain liked to childhood obesity: Study

Women who gain excessive weight during pregnancy have a greater chance their babies will be born too big. Scientists are trying to find whether this relationship of gaining too much weight by mother and baby is genetic and can predispose the child to be obese later in life.

4 Aug 2010

Conceptus’ Essure procedure effective for permanent birth control

According to the recently released 2006-08 National Survey of Family Growth by the Center for Disease Control, one in four women choose permanent birth control. Conceptus, Inc. wants women to know that its Essure permanent birth control procedure has been gaining in popularity, and is a safe and effective solution used by hundreds of thousands of women worldwide.

4 Aug 2010

FSU biologist-mathematician team receives $2.64 million grant to study prolactin secretion

A Florida State University biologist and mathematician have joined forces to find out exactly how the brain oversees the secretion of the hormone prolactin from the pituitary gland, research that could lead to new ways to treat hundreds of disorders, including infertility.

4 Aug 2010

Dendreon second-quarter revenue increases to $2.8 million

Dendreon Corporation today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009. Revenue for the six months ended June 30, 2010 was $2.8 million compared to $55,000 for the six months ended June 30, 2009.

4 Aug 2010

Hormone News and Research

Further Reading

Progestins have tumor-stage specific effects that determine promotion, suppression: Study

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

GTx second-quarter net loss increases to $12.9 million

Repros Therapeutics receives positive feedback from FDA for Androxal

Shlomo Melmed appointed to Independent Citizen's Oversight Committee

Surgery offers high survival rate for prostate cancer patients: Study

OncoGenex reports net income in second-quarter 2010 against loss last year

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Patheon, Dendreon announce signing of technology transfer agreement

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

New volume on Growth hormone therapy

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Excess maternal weight gain predicts high birth weight: Research

Scientists suggest home genetic tests may cause unnecessary stress

Pregnancy weight gain liked to childhood obesity: Study

Conceptus’ Essure procedure effective for permanent birth control

FSU biologist-mathematician team receives $2.64 million grant to study prolactin secretion

Dendreon second-quarter revenue increases to $2.8 million

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News